Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Pre-Procedural Guidelines for Assessing Blood Pressure01:10

Pre-Procedural Guidelines for Assessing Blood Pressure

573
Accurate blood pressure assessment is crucial for diagnosing and managing various health conditions. To ensure the reliability of these measurements, healthcare professionals must adhere to standardized pre-procedural guidelines. These guidelines enhance patient safety and improve the overall quality of healthcare. The following steps are essential for obtaining accurate and consistent blood pressure readings, from using the appropriate tools to ensuring effective communication with the...
573
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

14
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
14
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

23
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
23
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

17
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
17
Assessment of blood pressure in brachial artery(two-step method)01:23

Assessment of blood pressure in brachial artery(two-step method)

721
Measuring blood pressure is a fundamental skill in healthcare that aids in diagnosing and monitoring hypertension and other cardiovascular conditions. An aneroid sphygmomanometer, commonly used in clinical settings, offers a manual and precise method for blood pressure measurement. The technique for using this instrument involves specific steps that must be carefully executed to ensure accuracy. The following detailed description outlines a two-step technique for assessing blood pressure using...
721
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

15
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  2. 研究分野
  3. 生物医学と臨床科学
  4. 心血管医学と血液学
  5. 心臓病 (心血管疾患を含む)
  6. アメリカ心臓協会のprevent方程式の開発と検証

アメリカ心臓協会のPREVENT方程式の開発と検証

Sadiya S Khan1, Kunihiro Matsushita2, Yingying Sang2,3

  • 1Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.S.K.).

Circulation
|November 10, 2023

関連する実験動画

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:15

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

74
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.5K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.6K

PubMed で要約を見る

まとめ
この要約は機械生成です。

アメリカ心臓協会の新しいPREVENT方程式は,一般的な臨床的要因を用いて,米国の成人における心血管疾患 (CVD) のリスクを正確に予測します. これらの検証された方程式は,心血管疾患の初期予防のためのリスク評価を改善します.

キーワード:
心血管疾患心不全腎臓疾患モデル,心血管

関連する実験動画

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:15

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

74
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.5K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.6K

科学分野:

  • 心血管疾患の疫学
  • リスク予測モデリング
  • 予防的な心臓科

背景:

  • 心血管疾患 (CVD) リスク評価のための現在の多変量方程式には限界があります.
  • 主要予防ガイドラインは,CVDのリスク評価方程式を推奨しています.
  • 既存のCVDリスク予測の限界に対処するために新しい方程式が必要でした.

研究 の 目的:

  • CVD EVENT (PREVENT) のリスクを予測するアメリカ心臓協会の方程式を開発し,検証する.
  • 既知のCVDのない30歳から79歳の米国人のCVDリスクを評価する.
  • 伝統的なリスク因子と推定された球の濾過率を用いて性別特有の方程式を作成する.

主な方法:

  • 1992年から2017年までの25のデータセット (N=3,281,919) の個人レベルのデータを使用した.
  • 伝統的なCVDの危険因子 (喫煙,血圧,コレステロール,薬物使用,糖尿病) とeGFRを含む.
  • 性別別別別の,人種別モデルを競合するリスクに調整したメタアナリシスを実施し,外部で3,330,085人の参加者に検証した.

主要な成果:

  • 6, 612, 004人の成人; 追跡期間の中央値 4. 8年; 211, 515件のCVD事件.
  • 外部検証では,良好な差別化 (C統計の中位値: 0. 794 女性, 0. 757 男性) と校正 (斜率: 1. 03 女性, 0. 94 男性) が示された.
  • オプションの予測値 (尿中のアルブミンとクレアチニンの比率,HbA1c,社会的欠乏指数) を加えると,差別は小さく,しかし有意に改善された.

結論:

  • PREVENT方程式は,米国の大規模で多様な成人集団におけるインシデントCVDとCVDサブタイプを正確に予測します.
  • この方程式は,リスク予測のために日常的に利用可能な臨床変数を効果的に利用します.
  • これらの検証済みの方程式は 心血管疾患を予防するための 改善されたツールです
リスク評価
健康の社会的決定因子